Close Menu

The US Food and Drug Administration's 510(k) clearance in January of a cystic fibrosis carrier-detection assay on Osmetech's eSensor 4800 DNA Detection platform came six months after the company acquired the technology from Motorola.

The clearance, which Osmetech plans to follow in the second quarter with a launch, also places the company ahead of other array companies whose own assays are currently queuing at the FDA, including Spectral Genomics and PathWork Informatics (see BAN 1/24/2006).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.